TrialHuman vaccines & immunotherapeutics2012

Immunogenicity and safety results from a randomized multicenter trial comparing a Tdap-IPV vaccine (REPEVAX®) and a tetanus monovalent vaccine in healthy adults: new considerations for the management of patients with tetanus-prone injuries.

Henri Laurichesse et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.